A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Summary

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.

Timeline

Start

2022-08-31

Primary completion

2023-11-20

Completion

2025-01-17

Outcome

Met primary endpoint

Stopped: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.”

registry analysis (superiority test); Peresolimab 1000 mg SC Q4W vs Placebo SC Q4W; p = 0.014; Odds Ratio (OR) 1.88 (95% CI 1.14 to 3.11); NCT05516758 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peresolimab	Monoclonal antibody	100 mg	Subcutaneous
Subject	Peresolimab	Monoclonal antibody	400 mg	Subcutaneous
Subject	Peresolimab	Monoclonal antibody	1000 mg	Subcutaneous

Indications